Physician profile
Muhammad A Munir
NPI 1124079553
$8,167.72
in general payments reported to CMS, 2019-2025
34 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $609 · 2021: $1,154 · 2022: $987 · 2023: $1,576 · 2024: $1,570 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,399 · Travel and Lodging: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,399.35 |
| Travel and Lodging | $291.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,462.28 | 2019-2025 | Farxiga, Wainua, Breztri |
| Novartis Pharmaceuticals Corporation | $1,283.05 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $594.55 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $577.02 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $567.22 | 2021-2025 | Verquvo |
| Pfizer INC. | $364.78 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $352.58 | 2021-2025 | |
| Amgen INC. | $313.66 | 2019-2024 | Repatha |
| Glaxosmithkline, LLC. | $301.28 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Biosense Webster, INC. | $296.95 | 2025 | Carto 3 |
| Kestra Medical Technology Services, INC. | $254.96 | 2023-2025 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $166.22 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $159.05 | 2020-2024 | Wegovy |
| Boston Scientific Corporation | $152.08 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.04 | 2021-2025 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $142.43 | 2025 | Onpattro, Amvuttra |
| Medtronic, INC. | $131.90 | 2025 | Symplicity G3 |
| Madrigal Pharmaceuticals | $108.36 | 2024 | Rezdiffra |
| Medtronic Vascular, INC. | $101.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $99.54 | 2021-2025 | Camzyos, Eliquis |
| Regeneron Healthcare Solutions, INC. | $87.46 | 2019 | |
| Lilly USA, LLC | $69.76 | 2022-2024 | Jardiance, Zepbound |
| Esperion Therapeutics, INC. | $54.42 | 2021 | |
| Abiomed | $52.26 | 2023-2025 | Impella |
| Amarin Pharma, INC. | $46.29 | 2019-2020 | |
| Scpharmaceuticals INC. | $45.15 | 2024-2025 | |
| Impulse Dynamics (USA) INC. | $44.12 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $42.28 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $32.61 | 2025 | Opsumit, Uptravi |
| Preventice Services, LLC | $29.82 | 2019 | |
| Abbott Laboratories | $26.07 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.24 | 2025 | Caplyta |
| Allergan, INC. | $17.07 | 2020 | |
| Medicomp INC | $15.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.